Baystreet Staff -

Stonegate Capital Partners Initiates Coverage on Pulmatrix, Inc.


DALLAS, TX / ACCESSWIRE / December 16, 2015 / Stonegate Capital Partners initiates research coverage on Pulmatrix, Inc. (NASDAQ: PULM).

Company Description

Pulmatrix, Inc., is a clinical stage biopharma company developing inhaled therapies to address certain pulmonary diseases with its proprietary technology, iSPERSE(TM). The basis of the iSPERSE technology involves engineered spray-dried particles that enable the efficient delivery of inhaled therapeutics to the lungs. The iSPERSE technology platform can be utilized to create inhaled formulations for a wide range of therapeutics, including biologics. The company currently has an R&D collaboration with Mylan on its chronic obstructive pulmonary disease (COPD) candidate, PUR0200, a branded generic that has completed a Phase 1 trial in COPD patients. Pulmatrix also has two programs underway targeting rare diseases – an anti-fungal for the treatment of cystic fibrosis (CF) and an anti-fibrotic targeting idiopathic pulmonary fibrosis (IPF). The company is headquartered in Lexington, MA.


While the company is in the earlier stages of clinical development with its three drug candidates, Pulmatrix offers an opportunity for investors looking to participate in the development of pulmonary therapeutics targeting significant markets with a unique drug delivery platform:

- PUR0200 is Pulmatrix's lead product candidate, having completed a Phase 1b for patients with moderate to severe COPD. Results showed a significantly reduced effective dose compared to the reference product. In Europe, the company has partnered with Mylan to develop PUR0200, with additional trials to begin 1H16. PUR0200 could be the first branded generic of an estimated $5 billion worldwide market.

- Pulmatrix is developing PUR1900, which could become the first inhaled anti-fungal for CF representing a potential $300 MM opportunity. Specifically, PUR1900 is an iSPERSE formulation of Itraconazole targeting pulmonary aspergillus infections, estimated to affect over 60% of US adolescents and adults with CF. Additionally, PUR1900 could be developed for several other rare indications, where aspergillus arises.

- PUR1500 is a novel inhaled anti-fibrotic targeting IPF, advancing to clinical studies in the near-term with attractive market potential.

- The company's novel iSPERSE technology delivers therapeutics in an inhaled dry powder that supports increased drug loading and solves many formulation issues; thus, this platform is capable of delivering a wide range of APIs – small molecules, combinations, peptides, proteins, and biologics, including antibodies.

- In addition to its partnership with Mylan, Pulmatrix actively considers both in-licensing and out-licensing development prospects; the company recently announced a $1.7M NIH research grant to work with Celdara, Inc., on an inhaled anti-fibrotic labeled CM-YJH01.

- The company has a solid patent portfolio, with extensive protection surrounding its proprietary iSPERSE technology; to date, Pulmatrix reports 37 issued patents worldwide covering its IP through 2030.

- As most recently reported, the Company has approximately $22 million in cash on hand, which is expected to support continued development into mid-2017.

- Pulmatrix is well-positioned to leverage its novel iSPERSE technology in combination with the three drug candidates currently progressing within its pipeline. The Company has a current market capitalization of $56M and enterprise value of $40.7M versus comparable companies' median market capitalization of $175.1M and median enterprise value of $68.3M.

The full report can be accessed by clicking the following link:

About Stonegate Capital Partners

Stonegate Capital Partners is a Dallas-based corporate advisory firm dedicated to serving the specialized needs of small-cap public companies. Since our inception, our mission has been to find innovative, undervalued public companies for our network of leading institutional investors who seek high quality investment opportunities.

SOURCE: Stonegate Capital Partners